Windtree Therapeutics Inc Stock Price, News & Analysis

Windtree Therapeutics (NASDAQ:WINT) has announced a strategic partnership with Kraken, a major cryptocurrency platform, to provide custody, trading, and OTC services for Windtree's BNB Crypto Treasury Strategy. The partnership is contingent on shareholder approval of a previously announced securities purchase agreement that could bring up to $140 million in future subscriptions.

As the first NASDAQ-listed company offering direct exposure to the BNB token, which has a market cap exceeding $100 billion, Windtree will leverage Kraken's security infrastructure and expertise to manage digital assets and facilitate large-scale transactions. The Binance Smart Chain ecosystem, which BNB supports, processes over $2 billion in average daily trading volumes and hosts thousands of decentralized applications.

Windtree Therapeutics (NASDAQ:WINT) has announced a significant strategic shift with a $60 million securities purchase agreement led by Build and Build Corp, with potential additional subscriptions of up to $140 million. The company aims to become the first NASDAQ-listed entity offering direct exposure to the BNB token, the fifth-largest blockchain by market capitalization (over $95 billion).

The proceeds will primarily fund a BNB crypto treasury strategy, positioning Windtree as a pioneer in the Binance ecosystem. The transaction, subject to shareholder approval, will establish a comprehensive strategy including custody, security, and yield generation. BNB currently maintains average daily trading volumes exceeding $2 billion, making it the largest crypto exchange token globally.

Windtree Therapeutics (NASDAQ:WINT) has secured a new U.S. patent for istaroxime, its drug candidate for treating acute heart failure (AHF). The patent (application #18/150,870) covers istaroxime-containing intravenous formulation and extends protection until 2039.

The drug has already demonstrated success in two Phase 2 AHF studies and two early cardiogenic shock studies. This development is particularly significant as AHF affects 1.3 million hospitalized patients annually in the U.S. and represents the leading cause of hospitalization for patients over 65 years old.

Windtree Therapeutics (NASDAQ:WINT) has achieved its target enrollment of 20 patients for the interim analysis of its Phase 2 SEISMiC C study, evaluating istaroxime in SCAI Stage C cardiogenic shock patients. The study represents the third trial in the company's istaroxime cardiogenic shock development program, following two previously successful Phase 2 studies in SCAI Stage B patients.

The SEISMiC C trial is a global, placebo-controlled, double-blinded study conducted across the U.S., Europe, and Latin America. The study evaluates istaroxime in combination with standard care treatments, including inotropes and vasopressors. The primary endpoint focuses on systolic blood pressure profile during the first six hours of treatment.

The interim analysis will primarily assess preliminary safety, tolerability, and efficacy signals to determine appropriate sizing for the remainder of the trial. The company notes that a statistically significant efficacy signal is not expected at this interim stage. The data from this study will be crucial for Phase 3 readiness and upcoming FDA discussions.

Windtree Therapeutics (NASDAQ:WINT) has secured a contract with a Chinese pharmaceutical manufacturer to produce PHEXXI, Evofem's hormone-free contraceptive gel, at significantly reduced costs. The manufacturing agreement is expected to cut PHEXXI production costs by over 50% by the end of 2026.

The technology transfer process has begun, with early-stage manufacturing scheduled to start later in 2025. This arrangement, stemming from Windtree's March 2025 License and Supply Agreement with Evofem, is anticipated to generate revenue for Windtree starting in 2026. PHEXXI has shown four consecutive years of net sales growth, with plans for international expansion beginning with a marketing approval submission in the UAE.

Windtree Therapeutics (WINT) announced the publication of positive Phase 2 SEISMiC B study results for istaroxime in the Journal of Heart and Lung Transplantation. The study demonstrated significant efficacy in treating early cardiogenic shock, with istaroxime increasing blood pressure over 6 hours and maintaining effects for 60 hours. Key benefits included improved cardiac output, decreased pulmonary capillary wedge pressure, no increase in heart rate, no significant arrhythmias, and preserved renal function. The company is in partnership discussions to fund remaining clinical development, targeting the $1.25 billion cardiogenic shock market. Windtree plans to release interim data from the SEISMiC C trial in July and is finalizing Phase 3 protocol design for acute heart failure indication in China with a regional partner.

Windtree Therapeutics (WINT) has received a non-binding letter of intent to sell its preclinical oncology aPKCi inhibitor platform. The deal includes a $7.0 million upfront payment in cash or freely tradable stock, potential milestone payments up to $130 million, and high single-digit royalties that could reach $1.5 billion over the drug's lifetime. The agreement also includes options to acquire Windtree's cardiovascular drug candidates and its manufacturing agreement with Evofem Biosciences. The company has 21 days to close the oncology portion of the transaction. This move aligns with Windtree's new corporate strategy to focus on revenue-generating opportunities while reducing cash burn.

Windtree Therapeutics (WINT) has announced a transformative acquisition of Titan Environmental Services, marking its entry into the $85 billion US waste management market. The deal involves issuing preferred shares and securing debt financing, with Titan becoming a subsidiary renamed as Windtree Environmental Services. The acquisition is expected to generate $12 million in revenue over the next 12 months and includes an $8 million breakup fee protection. The company plans to retain Titan's management team and pursue a roll-up strategy in the fragmented waste management industry. This move represents a strategic shift for Windtree, which is actively seeking to divest or partner its pharmaceutical assets to reduce costs and increase profitability. The transaction is anticipated to close in Q3 2025.

Aditxt (ADTX) has appointed Evofem Biosciences CEO Saundra Pelletier to its Board of Directors. Pelletier brings over three decades of pharmaceutical industry experience, specializing in women's health. During her 10-year leadership at Evofem, she successfully led the company's public market transition and oversaw the approval of PHEXXI, a hormone-free contraceptive gel, and SOLOSEC, an antibiotic for bacterial infections. Her appointment aligns with Aditxt's strategy to expand into women's health monitoring, prevention, and treatment. Pelletier's extensive background includes roles at Woman Care Global and G.D. Searle, and she currently serves on multiple boards including Windtree Therapeutics.